8-K: Premier Inc. Exceeds FY25 Profit, Guides FY26 Lower

Premier, Inc. reported better-than-expected fiscal year 2025 financial results, driven by strong Supply Chain Services, but anticipates a decline in fiscal year 2026 before returning to growth in fiscal year 2027.

Summary

• Premier, Inc. reported fiscal year 2025 total net revenue of $1,012.6 million, an 11% decrease from fiscal year 2024.
• Full-year GAAP net income from continuing operations was $72.7 million, down 30% from $104.2 million in fiscal year 2024.
• Adjusted EBITDA for fiscal year 2025 was $253.1 million, a 35% decrease from $389.0 million in fiscal year 2024.
• Adjusted EPS for fiscal year 2025 was $1.46, a 30% decrease from $2.08 in fiscal year 2024.
• Fourth-quarter fiscal year 2025 total net revenue was $262.9 million, a 12% decrease from the prior-year period.
• Fourth-quarter GAAP net income from continuing operations was $18.0 million, a 70% decrease from $60.9 million in the prior-year period.
• Fourth-quarter adjusted EPS was $0.43, a 30% decrease from $0.61 in the prior-year period.
• Full-year net cash provided by operating activities from continuing operations was $417.8 million, an increase from $278.1 million in the prior year.
• Free cash flow for fiscal year 2025 was $180.5 million, compared to $228.0 million in the prior year.
• The company provided fiscal year 2026 guidance: total net revenue excluding Contigo Health of $940 million to $1 billion, adjusted EBITDA of $230 million to $245 million, and adjusted EPS of $1.33 to $1.43.
• The company expects to return to positive growth for total net revenue, adjusted EBITDA, and adjusted EPS in fiscal year 2027.
• The company completed an $800 million share repurchase under its $1 billion authorization, which expired on June 30, 2025.
• A quarterly cash dividend of $0.21 per share was declared, payable on September 15, 2025.
• Executive compensation packages for Andrew F. Brailo (Chief Commercial Officer) and David L. Klatsky (General Counsel) were increased, effective September 1, 2025, for base salaries and immediately for FY26 equity awards.

Sentiment

Score: 6

Explanation: While the company exceeded its FY25 guidance and has clear strategic positives like advisory momentum and the IllumiCare acquisition, the projected decline in FY26 revenue and profitability due to ongoing fee share headwinds and transition costs indicates a period of near-term challenges before an expected rebound in FY27. The completion of the TRA payments is a significant positive for future cash flow.

Positives

• Overall revenue and profitability for fiscal year 2025 exceeded expectations, largely due to better-than-anticipated performance in the Supply Chain Services segment.
• Supply Chain Services segment showed continued growth in member purchasing and increased utilization of contracts with existing and new members.
• The company completed a $200 million accelerated share repurchase program, bringing the total repurchased common stock to $800 million under its $1 billion authorization.
• The final payment associated with the Tax Receivable Agreement (approximately $100 million per year) was made in Q4 FY25, eliminating this negative impact on free cash flow starting July 1, 2025.
• The Performance Services segment is showing meaningful momentum in its advisory business, having recently signed four very large deals and building a robust pipeline.
• The acquisition of IllumiCare is expected to significantly strengthen the company's ability to deliver real-time insights at the point of care, leveraging AI capabilities, and offers a 10:1 return on investment for customers.
• Pharmacy and food portfolios continue to serve as key differentiators within the GPO, delivering steady, meaningful growth and attracting non-Premier organizations.
• Operating expenses were reduced by $40 million on an annual run rate basis in Q4 FY25, expected to result in a slight year-over-year reduction in FY26 operating expenses.
• Gross administrative fees grew over 3% in fiscal year 2025 and are expected to grow faster (around 4%) in fiscal year 2026.

Negatives

• Total net revenue for Q4 FY25 decreased 12% from the prior-year period, and full-year FY25 total net revenue decreased 11% from FY24.
• GAAP net income from continuing operations for Q4 FY25 decreased 70% and for full-year FY25 decreased 30% from prior periods.
• Adjusted EBITDA for Q4 FY25 decreased 34% and for full-year FY25 decreased 35% from prior periods.
• Net administrative fees revenue decreased 10% in Q4 FY25, primarily driven by an expected increase in the aggregate blended member fee share.
• Performance Services segment net revenue decreased 20% in Q4 FY25, primarily due to lower revenue in the consulting business and timing of license revenue.
• The company expects lower revenue and profitability in the first half of fiscal year 2026, mainly due to the ramp-up of headcount to support the advisory business.
• The fee share is anticipated to increase to the mid-60% range in fiscal year 2026 and stabilize in the high 60s on an annualized basis once all renewals are addressed.
• Supply Chain Services EBITDA margins are expected to decline in fiscal year 2026 due to the fee share reset.

Risks

• Mounting financial pressures on member hospitals and health systems, including reimbursement cuts, forcing them to rethink cost structures and long-term sustainability.
• Contract renewal headwinds, although mostly behind the company, continue to impact financial results in fiscal year 2026.
• The highly competitive nature of the market for executive talent poses a risk to retention and performance.
• Potential impacts on the company's operations and strategic plans in the event of the loss of key executives.
• Potential tariff impacts on supply chain costs, although current contracts are firm for the term, requiring ongoing work to minimize effects.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially.
• The ongoing transition and wind-down of the Contigo Health business may incur potential costs and expenses.

Future Outlook

The company expects fiscal year 2026 to be a year of stabilization and transition, with guidance for total net revenue excluding Contigo Health between $940 million and $1 billion, adjusted EBITDA between $230 million and $245 million, and adjusted EPS between $1.33 and $1.43. The first half of FY26 is expected to have lower revenue and profitability due to headcount ramp-up for advisory services, with margins improving later in the year. The company anticipates a return to positive growth across all key financial metrics in fiscal year 2027.

Management Comments

• "I'm pleased to report that we had a strong finish to the year despite the contract renewal headwinds, which are now mostly behind us. Our overall revenue and profitability for the year exceeded our expectations largely due to better-than-anticipated results in our Supply Chain Services segment."
• "We continued to return meaningful capital to stockholders through our quarterly cash dividend and the completion of a $200 million accelerated share repurchase program."
• "The breadth of our GPO portfolio, the depth of our advisory expertise and the promise of our technology are differentiating us in the market, enabling us to deliver measurable impact that scale and deepen our strategic partnerships across the health system landscape."
• "We recently signed four very large advisory deals and have a robust pipeline heading into fiscal 2026."
• "Our pharmacy and food portfolios have continued to serve as key differentiators within our GPO. Both are delivering steady, meaningful growth, not only among our current members, but also by attracting non-Premier organizations seeking distinctive high-impact savings with built-in supply assurance."
• "We expect to return to positive growth for total net revenue, adjusted EBITDA and adjusted EPS in fiscal year 2027."
• "We expect lower revenue and profitability in the first half of the year, mainly due to the ramp-up of headcount to support the recent success of our advisory business. Importantly, we anticipate this impact will be transitory, and that margins will improve as we begin to recognize the associated revenue later in the year."

Industry Context

The healthcare industry is facing mounting financial pressures, including reimbursement cuts, labor shortages, and rising costs, which are accelerating demand for value-based strategic support. Premier, Inc. is positioning itself to address these challenges by offering integrated data and analytics, collaboratives, supply chain solutions, consulting, and novel technologies. The company's focus on enterprise-wide transformation and clinical decision support, exemplified by the IllumiCare acquisition, aligns with the industry's need for improved clinical and financial performance. The continued growth in GPO's pharmacy and food portfolios highlights the ongoing demand for cost-saving solutions amidst these pressures.

Comparison to Industry Standards

• The IllumiCare acquisition is expected to deliver approximately $100 in savings per inpatient discharge for customers, representing a 10:1 return on investment, which is a significant and immediate return for healthcare providers facing margin compression.

Management Changes

Corporate Governance

Legal Proceedings

• Received cash from a derivative lawsuit settlement of $57.0 million in fiscal year 2025.

Related Party Transactions

• Cash payments to OMNIA for the sale of future revenues in connection with the sale of non-healthcare GPO member contracts.
• Early termination payments to certain former limited partners that elected to execute a Unit Exchange Agreement in connection with the August 2020 restructuring, with the final payment made in Q4 FY25.

Stakeholder Impact

• **Shareholders**: Benefited from the completion of an $800 million share repurchase program and quarterly cash dividends. Expected to see a return to positive growth in key financial metrics in fiscal year 2027 after a transitional fiscal year 2026.
• **Employees**: The company is ramping up headcount in its advisory business, indicating job growth in that segment. Executive compensation adjustments aim to retain key talent.
• **Customers (Healthcare Providers)**: The company is actively addressing their mounting financial pressures (reimbursement cuts, cost structures) by providing value-based strategic support, GPO solutions, advisory expertise, and technology. The IllumiCare acquisition is specifically designed to deliver significant cost savings per inpatient discharge.
• **Suppliers**: The company is working in concert with suppliers to minimize the impacts of potential tariffs, indicating ongoing collaboration and negotiation.

Next Steps

• File Form 10-K for the year ended June 30, 2025, shortly after the earnings release.
• Continue efforts to transition to partners or wind down certain components of the Contigo Health business, expected to be substantially complete by December 31, 2025.
• Execute on recently signed large advisory deals and continue to build the pipeline for future opportunities.
• Integrate IllumiCare acquisition to further expand clinical decision support capabilities and drive double-digit growth.
• Continue organic investments and potential tuck-in acquisitions to enhance core offerings.
• Address remaining GPO contract renewals (less than 20% of the August 2020 restructured group's fees remain, majority expected to be addressed in FY26).

Key Dates

Recommendation

Premier, Inc. is navigating a transitional period. While the company exceeded its fiscal year 2025 guidance and has strong strategic initiatives like the growing advisory business and the IllumiCare acquisition, the projected decline in fiscal year 2026 revenue and profitability due to ongoing fee share headwinds and the Contigo Health wind-down creates near-term uncertainty. The positive impact of the completed TRA payments on future free cash flow is a significant long-term benefit. Investors should hold to observe the successful execution of the advisory business ramp-up and the anticipated return to growth in fiscal year 2027, as the company moves past its contract renewal cycle.

Keywords

Healthcare, Supply Chain Services, Performance Services, GPO, Group Purchasing Organization, Healthcare Technology, Financial Results, Earnings, SEC Filing, PINC, Advisory Services, Clinical Decision Support, Share Repurchase, Dividends